The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

All under-40s to be offered alternative to AstraZeneca vaccine

Fri, 7th May 2021 08:49

(Alliance News) - All under-40s in the UK are to be offered an alternative to the Oxford University and AstraZeneca PLC Covid vaccine in a precautionary move.

The Joint Committee on Vaccination & Immunisation and the Medicines & Healthcare products Regulatory Agency are expected to say there are no new safety concerns after previous data showed the AstraZeneca jab was linked to very rare blood clots.

Previously, the MHRA has said the balance of risk for the AstraZeneca vaccine against Covid is very favourable for older people but "more finely balanced" for younger groups, who do not tend to suffer serious coronavirus illness.

Up to April 28, the MHRA had received 242 reports of blood clots accompanied by low blood platelet count in the UK, all in people who had AstraZeneca, out of around 28.5 million doses given.

These clots occurred in 141 women and 100 men aged from 18 to 93, and the overall case death rate was 20%, with 49 deaths. Six cases have been reported after a second dose of the vaccine.

A particular type of brain blood clot – cerebral venous sinus thrombosis – was reported in 93 cases with an average age of 47, and 149 with an average age of 55 had other major thromboembolic events accompanied by low blood platelet count.

The MHRA and JCVI have both said that the benefits of the AstraZeneca vaccine continue to "outweigh the risks for the vast majority of adults".

By Jane Kirby, PA Health Editor

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

Wednesday broker round-up

(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.

23 Jun 21 13:04

Delta plus variant reclassified as 'variant of concern', experts sanguine for now

(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".

23 Jun 21 10:47

AstraZeneca's 'Orpathys' gets conditional approval in China

(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.

23 Jun 21 07:33

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

22 Jun 21 20:16

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.